Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Common Equity (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Common Equity for 6 consecutive years, with $141.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 49.56% to $141.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $141.8 million, a 49.56% decrease, with the full-year FY2024 number at $253.0 million, down 31.34% from a year prior.
  • Common Equity was $141.8 million for Q3 2025 at Caribou Biosciences, down from $166.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $404.4 million in Q3 2021 to a low of -$47.7 million in Q2 2021.
  • A 5-year average of $267.4 million and a median of $300.9 million in 2022 define the central range for Common Equity.
  • Biggest YoY gain for Common Equity was 3707.18% in 2021; the steepest drop was 1599.48% in 2021.
  • Caribou Biosciences' Common Equity stood at $387.8 million in 2021, then dropped by 22.42% to $300.9 million in 2022, then increased by 22.44% to $368.4 million in 2023, then crashed by 31.34% to $253.0 million in 2024, then crashed by 43.92% to $141.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Common Equity are $141.8 million (Q3 2025), $166.1 million (Q2 2025), and $217.2 million (Q1 2025).